Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page’s revision label was updated from v3.5.2 to v3.5.3, indicating a new revision of the page content. This change is a metadata-level patch rather than a substantive update to the study information.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRevision metadata updated: added Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page now shows Revision: v3.5.0, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a system-level update with no visible changes to the study details on the page.SummaryDifference0.0%

- Check92 days agoChange DetectedAn administrative revision tag (v3.4.2) was added and previously displayed notices about government funding and operating status were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check99 days agoChange DetectedAdded a government funding lapse notice banner. Updated the page revision tag from v3.4.0 to v3.4.1.SummaryDifference0.3%

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.